BioSpring

Executive Summary

BioSpring, founded in 1997 and headquartered in Frankfurt, Germany, is a private contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics. The company provides GMP-compliant synthesis, analysis, and regulatory support for oligonucleotides and mRNA across all clinical phases, from preclinical research to commercial supply. With over two decades of experience, BioSpring has established itself as a global leader and trusted partner for pharmaceutical and biotech companies developing advanced genetic medicines. The CDMO's expertise spans a range of modalities, including antisense oligonucleotides, siRNA, and mRNA, catering to the growing demand for genetic therapies. As the nucleic acid therapeutics market expands, driven by approvals of RNA-based drugs and vaccines, BioSpring is well-positioned to benefit from increased outsourcing of manufacturing and development services. The company's long-standing track record and strategic focus on high-quality, customized solutions underpin its reputation in the field.

Upcoming Catalysts (preview)

• Q4 2026New partnership with a top-20 pharma for oligonucleotide GMP manufacturing60% success
• Q2 2027Completion of facility expansion to increase mRNA production capacity80% success
• H2 2026Regulatory approval of a client's nucleic acid therapeutic manufactured by BioSpring50% success